Skip to content

Analysis of Prognosis, Clinical-Pathological, and Metabolic Characteristics in Patients with Pancreatic Cancer Complicated by Lipopancreatitis

Prognostic, Clinicopathological and Metabolic Characteristics of Pancreatic Cancer Patients with Pancreatic Steatosis: A Single-Center Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128580
Enrollment
Unknown
Registered
2026-07-22
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Non-Fatty Pancreas Group:None
Adipose-Pancreatic Group:None

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Be 18 years old or above; 2. Preoperative diagnosis is considered pancreatic cancer; 3. Radical surgical resection was performed, and the postoperative pathology confirmed pancreatic cancer; 4. Complete imaging data are available before the operation, and the status of pancreatic fat infiltration can be evaluated through CT.

Exclusion criteria

Exclusion criteria: 1.The patient had already received anticancer treatment prior to surgery. 2.In addition to pancreatic cancer, a history of other malignant tumors or concurrent malignant tumors; 3.The patient's pathology data is incomplete, so the tumor grade cannot be determined.

Design outcomes

Primary

MeasureTime frame
Clinical and pathological changes include tumor type, tumor location (pancreatic head/body/tail), maximum tumor diameter (cm), Ki-67 index, tumor grade (G1/G2/G3), and TNM stage (based on AJCC 9th Edition criteria).;Metabolic indicators mainly include the results of the most recent preoperative lipid test, such as high-density lipoprotein cholesterol, triglycerides, total cholesterol, low-density lipoprotein cholesterol, as well as fasting blood glucose and glycated hemoglobin.;

Secondary

MeasureTime frame
Progression-Free Survival;Overall Survival;

Countries

China

Contacts

Public ContactZhan Hanxiang

Qilu Hospital of Shandong University

zhanhanxiang@hotmail.com+86 531 82166351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026